GALT Earnings

Quarterly EPS
$-0.18
Q3 2024
$-0.19
Q4 2024
$-0.15
Q1 2025
$-0.12
Q2 2025
$-0.13
Q3 2025
$-0.09
Q4 2025
$-0.08
Q1 2026
$-0.14
Q2 2026
Latest RevenueN/A
Latest Net Income-9113000
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q2 2026-$0.140-9113000-16.7%
Q1 2026-$0.080-5046000+46.7%
Q4 2025-$0.090-5500000+52.6%
Q3 2025-$0.130-8184000+27.8%
Q2 2025-$0.120-7521000+40.0%
Q1 2025-$0.150-9631000+21.1%
Q4 2024-$0.190-11967000-18.8%
Q3 2024-$0.180-11220000+25.0%
Q2 2024-$0.200-12371000
Q1 2024-$0.190-11489000
Q4 2023-$0.160-9997000
Q3 2023-$0.240-10428000
Galectin Therapeutics (GALT) — Earnings